Insider Buying: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Buys 60,000 Shares of Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Jan Skvarka bought 60,000 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were purchased at an average cost of $1.72 per share, with a total value of $103,200.00. Following the completion of the transaction, the director now owns 149,551 shares in the company, valued at $257,227.72. This represents a 67.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $1.63 on Wednesday. Zentalis Pharmaceuticals, Inc. has a 1-year low of $1.61 and a 1-year high of $18.07. The stock’s fifty day moving average price is $2.87 and its 200 day moving average price is $3.23.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.36. Sell-side analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZNTL. Barclays PLC lifted its position in Zentalis Pharmaceuticals by 18.5% during the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock worth $277,000 after acquiring an additional 11,748 shares during the period. GSA Capital Partners LLP lifted its position in Zentalis Pharmaceuticals by 138.5% during the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock worth $2,240,000 after acquiring an additional 353,384 shares during the period. Verition Fund Management LLC lifted its position in Zentalis Pharmaceuticals by 172.1% during the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after acquiring an additional 951,500 shares during the period. Primecap Management Co. CA lifted its position in Zentalis Pharmaceuticals by 21.6% during the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock worth $5,513,000 after acquiring an additional 265,690 shares during the period. Finally, Algert Global LLC acquired a new stake in Zentalis Pharmaceuticals during the 2nd quarter worth about $78,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ZNTL shares. Guggenheim decreased their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Wells Fargo & Company cut their price target on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a report on Thursday, January 30th. HC Wainwright cut their price target on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 29th. Wedbush reiterated a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Finally, UBS Group cut their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.